DIL
CNTX icon

Deeter Investments LLP’s Context Therapeutics CNTX Stock Holding History

Deeter Investments LLP’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$147K Buy
+100,000
New +$117K 0.03% 99

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Deeter Investments LLP's CNTX Position: Q4 2025 in Review

Deeter Investments LLP opened a new position in Context Therapeutics (CNTX) in Q4 2025: 100,000 shares worth $147K. The stake represents 0.03% of the portfolio and ranks #99 among its holdings.

43 funds tracked by Wall St. Rank hold CNTX as of Q4 2025.

  • Deeter Investments LLP held 100,000 shares of Context Therapeutics worth $147K as of Q4 2025.
  • Context Therapeutics was a new Deeter Investments LLP position in Q4 2025.
  • Context Therapeutics made up 0.03% of Deeter Investments LLP's portfolio in Q4 2025, its #99 holding.
  • 43 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2025.

Based on Deeter Investments LLP's 13F filing for Q4 2025, filed 28 Aug 2026.